Drugs / MRTX0902
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05578092 | Dec 2022 → Feb 2026 | colorectal cancer, non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRTX0902 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05578092 ↗ |
| Known as | UNII-CRG69FR93G | ChEMBL registry synonym — accepted as the source's own label CHEMBL5192659 ↗ |
| Action | Inhibit | “SOS1 inhibitor” NCT05578092 ↗ |
| Modality | Small molecule | — CHEMBL5192659 ↗ |
| Target | SOS1 | “SOS1 inhibitor” NCT05578092 ↗ |